866-997-4948(US-Canada Toll Free)

Herpes Zoster (Shingles) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Apr 2017

Category :

Pharmaceutical

No. of Pages : 63 Pages

Herpes Zoster (Shingles) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) Pipeline Review, H1 2017, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 3, 1, 1, 6 and 1 respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) - Overview
Herpes Zoster (Shingles) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Herpes Zoster (Shingles) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Beijing Minhai Biotechnology Co Ltd
ContraVir Pharmaceuticals Inc
Epiphany Biosciences Inc
Foamix Pharmaceuticals Ltd
GeneOne Life Science Inc
GlaxoSmithKline Plc
Merck & Co Inc
NAL Pharmaceuticals Ltd
NanoViricides Inc
SK Chemicals Co Ltd
TSRL Inc
XBiotech Inc
Herpes Zoster (Shingles) - Drug Profiles
acyclovir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amenamevir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FV-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GLS-5100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-1437173A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
herpes zoster vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAL-3223 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-608 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Shingles - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TSR-087 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
V-212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valomaciclovir stearate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Zoster (Shingles) - Dormant Projects
Herpes Zoster (Shingles) - Discontinued Products
Herpes Zoster (Shingles) - Product Development Milestones
Featured News & Press Releases
Apr 18, 2017: GSK announces regulatory submission in Japan of its candidate vaccine for prevention of shingles
Feb 24, 2017: In First Phase 3 Trial, Merck's Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects
Nov 25, 2016: GSK announces EU regulatory submission of candidate vaccine for prevention of shingles - Follows regulatory submissions in US and Canada
Oct 27, 2016: GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
Oct 24, 2016: GSK announces US regulatory submission of candidate vaccine for prevention of shingles
Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles
Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug
Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study
Oct 27, 2015: GSKs candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over
Sep 08, 2015: Clinical trial for Cardiffs shingles treatment
Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain
Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial
Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied
Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Herpes Zoster (Shingles), H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Herpes Zoster (Shingles) - Pipeline by Astellas Pharma Inc, H1 2017
Herpes Zoster (Shingles) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
Herpes Zoster (Shingles) - Pipeline by ContraVir Pharmaceuticals Inc, H1 2017
Herpes Zoster (Shingles) - Pipeline by Epiphany Biosciences Inc, H1 2017
Herpes Zoster (Shingles) - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Herpes Zoster (Shingles) - Pipeline by GeneOne Life Science Inc, H1 2017
Herpes Zoster (Shingles) - Pipeline by GlaxoSmithKline Plc, H1 2017
Herpes Zoster (Shingles) - Pipeline by Merck & Co Inc, H1 2017
Herpes Zoster (Shingles) - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
Herpes Zoster (Shingles) - Pipeline by NanoViricides Inc, H1 2017
Herpes Zoster (Shingles) - Pipeline by SK Chemicals Co Ltd, H1 2017
Herpes Zoster (Shingles) - Pipeline by TSRL Inc, H1 2017
Herpes Zoster (Shingles) - Pipeline by XBiotech Inc, H1 2017
Herpes Zoster (Shingles) - Dormant Projects, H1 2017
Herpes Zoster (Shingles) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Herpes Zoster (Shingles), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *